Recommended offer for Concateno
Article Date: Jun 05 2009AIM-listed drug abuse testing specialist Concateno has reached an agreement on a recommended offer from US-based Inverness Medical Innovations. The offer values the business at an enterprise value of £147 million and the overall consideration is equivalent to 121.24p per share, made up of 79p in cash and the balance in Inverness common stock. The company's share price yesterday was 107p and it has increased to 115.75p on the news
